NEW YORK (GenomeWeb News) – SuperNova Diagnostics today said that it has signed a collaboration agreement with Shenzhen Kang Bao Bio-Technology.
The Germantown, Md.-based startup did not say what functions KSB Diagnostics will be performing on its behalf, but noted that the Hong Kong firm specializes in the research, manufacture, and distribution of in vitro diagnostic kits and research reagents in China and other markets in the area.
"This collaborative relationship allows SuperNova and KSB to expand R&D, manufacturing, and commercialization into one of the world's largest markets," SuperNova President and CEO Neil Campbell said in a statement.
SuperNova, which initially was based in Hong Kong but set up shop in the US a couple of years ago, has developed the AmpCrystal molecular diagnostics platform. The technology is based on liquid crystal display and uses hyper-dense, energy-mediated nanocrystals in an effort to overcome the limitations inherent in current molecular and immunoassay technologies.